Hanmi Science, the holding company of Hanmi Pharm, announced a significant restructuring, welcoming OCI Group as its major shareholder and establishing a joint management system.The move, made public on Saturday last week, was a surprise to many, including Hanmi Pharm CEO Lim Jong-yoon, who expresse
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent -- GC Cell, a notable player in the biotechnology field, is increasingly making its mark in the area of cell and gene therapy (CGT).Under the guidance of CEO James Park, who was appointed in March 2023, the company is acti
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent -- Seo Jin-seok, Celltrion Group Founder and co-Chairman Seo Jung-jin's eldest son and co-Chairman of the Board of Directors of Celltrion, made his first international conference debut on Wednesday at the J.P. Morgan Healt
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent --Celltrion Group Founder and Co-Chairman Seo Jung-jin promised that the company will continue to develop and manufacture biosimilars until all seven billion people in the world have access to affordable treatments.Speakin
SAN FRANCISCO, Calif.— By Lee Han-soo, Korea Biomedical Review correspondent -- Yuhan Corp. aims to catch the eye of foreign investors and potential drug development partners at the J.P. Morgan Healthcare Conference (JPMHC) 2024 by unveiling its ambitious drive to become one of the top 50 global pha
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent –- Kakao Healthcare CEO Hwang Hee took the stage at the J.P. Morgan Healthcare Conference (JPMHC) 2024 in San Francisco, Calif., on Tuesday, unveiling ambitious plans for PASTA, its new mobile-based blood sugar management
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent -- At the J.P. Morgan Healthcare Conference (JPMHC) 2024 being held in San Francisco from Monday to Thursday, Samsung Biologics presented a detailed overview of its strategic vision and accomplishments.Samsung Biologics CE
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent – Lotte Biologics, under the leadership of CEO Richard Lee, has once again made a notable appearance at the 42nd annual JPMorgan Healthcare Conference (JPMHC) on Tuesday.The JPMHC is ongoing in San Francisco from Monday to
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent –Flagship Pioneering, a company specializing in bioplatform innovation, and Samsung have announced a collaboration to enhance biopharmaceutical innovation on Monday. This partnership aims to utilize advanced technologies i
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent – The J.P. Morgan Healthcare Conference kicked off its 42nd annual conference at the Westin St. Francis San Francisco on Monday, with investors attending the event showing a lot of excitement about the prospect of a revita
Huons Meditech said it has obtained import approval for TULSA-PRO, a prostate cancer and benign prostatic hyperplasia treatment device, developed by Profound, a Canadian medical device company.TULSA-PRO is a treatment device based on ultrasound technology. The technology propagates through biologica
Dong-A ST said Accord Biopharma, a subsidiary of Intas Pharmaceutical, has received approval for the latter's biologics license application (BLA) for DMB-3115, a biosimilar referencing Stelara (ingredient: ustekinumab) to the FDA.Accord Biopharma had previously submitted the application to the FDA i
AstraZeneca Korea said that the Ministry of Food and Drug Safety (MFDS) approved Ultomiris (ingredient: ravulizumab) as an adjunct therapy for adults with antibody-positive acetylcholine receptor (AChR) generalized myasthenia gravis (gMG) on Thursday.Ultomiris had been approved for the treatment of
Korea recorded a trade deficit due to the global economic downturn in 2023, despite achieving the highest export volume in December.Notably, the biotech and healthcare industry, one of the five promising sectors, has experienced a continuous deficit for 16 months since July 2022.Despite an increase
GC Cell said that BioCentriq, its U.S. affiliate focused on cell and gene therapy (CGT) contract development and manufacturing organization (CDMO), successfully raised a total of $29.2 million in a Series A funding.BioCentriq was acquired by GC Cell and Green Cross Holdings in 2022. The company, bas
Dong-A ST said it has signed a licensing agreement with SK biopharmaceuticals for the epilepsy drug cenobamate in 30 countries, including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkey.The deal excludes the U.S. as cenobamate has been commercially available in the U.
Humasis, a medical diagnostics company, said on Wednesday that it filed a complaint with the Fair Trade Commission (FTC) against Celltrion, a biosimilar giant, for violating the Act on Fair Transactions in Subcontracting.The FTC filing comes after Humasis is undergoing a legal battle against Celltri
A Severance Hospital research team has newly identified a cause of retinoblastoma.Retinoblastoma is a white tumor that occurs in the retina and is the most common malignant tumor inside the eye of children. It can occur in one or both eyes. The most common symptom is a white pupil due to the tumor,
Korean pharmaceutical and biotech firms are set to participate in the upcoming J.P. Morgan Healthcare Conference, the world's largest healthcare conference known for capturing the interest of institutional investors. The event is scheduled to commence in San Francisco, the U.S., from Jan. 8-11.The c
Medytox, a Korean botulinum toxin (BTX) maker, said it has established a U.S. subsidiary Luvantas to advance into the global market with MT10109L, its non-animal-derived liquid BTX formulation.The company had submitted a biologics license application (BLA) for MT10109L to the FDA in late December. T